Literature DB >> 20652568

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.

Sebastian Scholl, Baerbel Spies-Weisshart, Anne Klink, Lars-Olof Muegge, Hans-Joerg Fricke, Andreas Hochhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20652568     DOI： 10.1007/s00277-010-1027-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Authors:  Weiguo Zhang; Chen Gao; Marina Konopleva; Ye Chen; Rodrigo O Jacamo; Gautam Borthakur; Jorge E Cortes; Farhad Ravandi; Abhijit Ramachandran; Michael Andreeff
Journal:  Clin Cancer Res       Date:  2014-03-11       Impact factor: 12.531

2.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

3.  Retracted Article: LncRNA ZEB2-AS1 regulates the drug resistance of acute myeloid leukemia via the miR-142-3p/INPP4B axis.

Authors:  Kai Wang; Jing Dai; Tao Liu; Qiong Wang; Yingxu Pang
Journal:  RSC Adv       Date:  2019-12-02       Impact factor: 4.036

4.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.